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Introduction: Prostate-specific antigen (PSA) bounce after brachytherapy has been well-
documented.This phenomenon has also been identified in patients undergoing stereotactic
body radiation therapy (SBRT). While the parameters that predict PSA bounce have been
extensively studied in prostate brachytherapy patients, this study is the first to analyze the
clinical and pathologic predictors of PSA bounce in prostate SBRT patients.
Materials and Methods: Our institution has maintained a prospective database of patients
undergoing SBRT for prostate cancer since 2006. Our study population includes patients
between May 2006 and November 2011 who have at least 18 months of follow-up. All
patients were treated using the CyberKnife treatment system. The prescription dose was
35–36.25 Gy in five fractions.
Results: One hundred twenty patients were included in our study. Median PSA follow-up
was 24 months (range 18–78 months). Thirty-four (28%) patients had a PSA bounce. The
median time to PSA bounce was 9 months, and the median bounce size was 0.50 ng/mL.
On univariate analysis, only younger age (p=0.011) was shown to be associated with an
increased incidence of PSA bounce. Other patient factors, including race, prostate size,
prior treatment by hormones, and family history of prostate cancer, did not predict PSA
bounces. None of the tumor characteristics studied, including Gleason score, pre-treatment
PSA,T-stage, or risk classification by NCCN guidelines, were associated with increased inci-
dence of PSA bounces. Younger age was the only statistically significant predictor of PSA
bounce on multivariate analysis (OR= 0.937, p=0.009).
Conclusion: PSA bounce, which has been reported after prostate brachytherapy, is also
seen in a significant percentage of patients after CyberKnife SBRT. Close observation rather
than biopsy can be considered for these patients. Younger age was the only factor that
predicted PSA bounce.
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INTRODUCTION
Prostate cancer remains the most commonly diagnosed non-
cutaneous cancer in men (1). Stereotactic body radiation ther-
apy (SBRT) is an emerging modality in the treatment of low-
and intermediate-risk prostate cancer, with several series showing
excellent local control and toxicity (2–5).
Prostate-specific antigen (PSA) bounce after brachytherapy
has been well-documented (6–9). The etiology of this phenom-
enon is unclear; proposed explanations include laboratory error
(10), a delayed radiation effect (8), and prostatitis secondary to
needle insertion (11). PSA bounce has also been identified in
three-dimensional conformal radiation therapy (3D-CRT) (12)
and intensity-modulated radiation therapy (IMRT) (13). There
have been a limited number of studies reporting the incidence of
PSA bounce after SBRT, which has varied from 17 to 31% in the
literature (2–5, 14). While the clinical, pathologic, and dosimetric
parameters that predict PSA bounce have been extensively studied
in patients undergoing permanent seed prostate brachytherapy,
to our knowledge no study has performed a similar analysis in
patients undergoing SBRT. This study reports our institution’s
incidence of PSA bounce in prostate SBRT, as well as performs
an analysis of clinical and pathologic predictors of PSA bounce in
this patient population.
MATERIALS AND METHODS
PATIENT POPULATION
Our institution has maintained a prospective database of patients
undergoing SBRT for prostate cancer since 2006. This study was
approved by our hospital’s institutional review board. One hun-
dred twenty patients with organ-confined prostate cancer treated
between May 2006 and November 2011 with follow-up of at least
18 months were included. No patients were treated with hormones
during or following treatment, but patients with prior treatment
with hormones were included.
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TREATMENT TECHNIQUE
All patients were treated using the CyberKnife treatment sys-
tem. The CyberKnife system consists of a 6-MV linear accelerator
mounted on a robotic arm. There are two orthogonal kilovolt-
age X-ray imagers that provide real time image guidance and
automatic correction for movement of the prostate throughout
the treatment. Approximately 2 weeks before treatment planning,
four fiducial seeds were placed transperineally in each patient to
allow for motion tracking during treatment. The four implanted
seeds were positioned with two at the prostate apex and two at the
base. After allowing approximately 1 week for possible seed migra-
tion, treatment planning was performed prior to the treatment day
using a CT scan (1.5-mm cuts) fused to an MRI. All pre-treatment
imaging was performed with the patient in the same position used
for treatment delivery. For low-risk patients, the prostate alone
was the gross target volume (GTV). For intermediate- to high-risk
patients, the proximal half of the seminal vesicles was added to the
GTV if the Gleason Score>6 and the PSA>10 ng/mL. Following
delineation of the GTV, a margin was added to create the planning
target volume (PTV). For low- and intermediate-risk patients, the
margin was 5 mm throughout except posteriorly by the rectum
where a 3-mm margin was used. For high-risk patients, an 8-mm
margin was added on the involved side. Target tracking and patient
positioning were accomplished by registering the location of the
fiducial markers in the real time images to their planning CT loca-
tion. The robotic delivery system automatically adjusts the linear
accelerator position to correct for both rotational and translational
movement of the patient and prostate during treatment. The total
clinical accuracy for treatment is less than 1 mm. Treatments were
delivered on five consecutive days. Patients had a bowel prepa-
ration prior to treatment, including Dulcolax (Boehringer, Ger-
many) and a fleet enema on the morning of each treatment. Addi-
tionally, patients received 1500 mg of amifostine (MedImmune,
LLC, Gaithersburg, MD, USA) mixed in saline as a rectal suppos-
itory at least 15–20 min prior to each treatment as a radioprotec-
tant. The prescription dose was 35–36.25 Gy in five fractions.
FOLLOW-UP
Routine PSA follow-up was performed at 3-month intervals for
the first 2 years, 4-month intervals for the following year, and 6-
month intervals thereafter. PSA bounce was defined as a rise of
0.2 ng/mL above a patient’s PSA nadir, followed by a decline in PSA
to below that nadir (6). Time to PSA bounce was calculated from
the first PSA measurement that was≥0.2 ng/mL above the patient’s
nadir (8). PSA bounce size was defined from the PSA nadir to the
subsequent PSA peak before falling below the prior nadir.
STATISTICAL ANALYSIS
Univariate analysis was performed using Pearson chi-squared tests
for categorical variables and Mann–Whitney U tests for categori-
cal variables. Multivariate analysis was performed using logistic
regression. All statistical analysis was done in SPSS 21 (IBM,
Armonk, NY, USA).
RESULTS
One hundred twenty patients were included in our study. Demo-
graphic, tumor, and treatment characteristics are summarized in
Table 1 | Patient and tumor characteristics.
Age 68.1 (47–88)
Prostate size 69.9 (24–201)
Pre-Tx PSA 5.5 (1–34)
NCCN RISK
Low 69 (58%)
Intermediate 38 (32%)
High 13 (11%)
GLEASON SCORE
≤6 73 (61%)
7 35 (29%)
8 10 (8%)
9 1 (1%)
Unknown 1 (1%)
DOSE
19.5 2 (2%)
21 4 (3%)
35 63 (53%)
36.25 51 (43%)
T-STAGE
T1 102 (85%)
T2 17 (14%)
Recurrence 1 (1%)
RACE
White 88 (73%)
Black 14 (12%)
Spanish 7 (6%)
Other 11 (9%)
FAMILY HISTORY OF PROSTATE CANCER
Yes 27 (23%)
No 93 (78%)
PRIOR HORMONES
Yes 11 (9%)
No 109 (91%)
NCCN, National Comprehensive Cancer Network; Tx, treatment; PSA, prostate-
specific antigen.
Table 1. The average age was 68.1 years (range 47–88 years). Using
NCCN guidelines, 69 (58%) patients were low-risk, 38 patients
were intermediate-risk (32%), and 13 patients were high-risk.
Seventy-three (61%) patients were Gleason score 6 or less, 35
(29%) patients were Gleason score 7, and 11 patients were Gleason
score 8 or higher. Median prostate size was 69.9 g (range 24–201 g).
Median PSA follow-up was 24 months (range 18–78 months).
Thirty-four (28%) patients had a PSA bounce. The median time
to PSA bounce was 9 months, and the median bounce size was
0.50 ng/mL. Table 2 summarizes the univariate analysis of patient
and tumor characteristics on the incidence of PSA bounces. Only
younger age (p= 0.011) was shown to be associated with an
increased incidence of PSA bounce. Other patient factors, includ-
ing race, prostate size, prior treatment by hormones, and family
history of prostate cancer, did not predict PSA bounces. None of
the tumor characteristics studied, including Gleason score, pre-
treatment PSA, T-stage, or risk classification by NCCN guidelines,
were associated with increased incidence of PSA bounces. On
Frontiers in Oncology | Radiation Oncology January 2014 | Volume 4 | Article 8 | 2
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Vu et al. PSA bounce after SBRT
multivariate analysis, younger age was the only statistically sig-
nificant predictor of PSA bounce (OR= 0.937, 95% confidence
interval= 0.892–0.984, p= 0.009).
DISCUSSION
The reported rate of PSA bounce after SBRT has varied from 17 to
31% in the literature (2–5, 14). Table 3 summarizes the results of
these studies. Our hospital’s experience is in-line with other insti-
tutions’ reported frequencies of PSA bounces. With institutions
reporting PSA bounces in 3D-CRT (12) and IMRT (13), the PSA
bounce phenomenon is seen in external beam radiation therapy
(EBRT) as well as in brachytherapy.
Varying definitions of PSA bounce have been used in the liter-
ature. Some have used an absolute increase (e.g., 0.4 ng/mL) from
the previous PSA (9), while others have used a relative increase
(e.g., 15%) from the most recent PSA (15). The rate of reported
PSA bounce will increase as lower thresholds of PSA bounce are
Table 2 | Univariate analysis of PSA bounces.
Variable P -value
PATIENT
Age 0.011
Race 1.00
Family history 0.75
Prior hormones 0.94
Prostate size 0.46
TUMOR
T-stage 0.62
Gleason score 0.19
Pre-Tx PSA 0.77
NCCN risk 0.45
PSA, prostate-specific antigen; Tx, treatment; NCCN, National Comprehensive
Cancer Network.
used. For example, Stock et al. (9) reported a PSA bounce rate of
31% if a 0.1 ng/mL threshold was used, while the PSA bounce rate
in the same population would be 17% if a 0.4 ng/mL threshold
was used.
To our knowledge, this is the first study of the clinical factors
that predict PSA bounce in prostate cancer patients undergoing
SBRT. In a recently published multi-institutional phase I feasibil-
ity study of 45 patients, McBride et al. found that prostate SBRT
patients with PSA bounces were younger than those who did not
have a PSA bounce (5). However, their study only analyzed the
effect of age and not the effects of other clinical and pathologic
parameters.
The predictors of PSA bounce in patients undergoing perma-
nent seed brachytherapy has been extensively discussed and was
reviewed by Caloglu and Ciezki (7). While a multitude of different
clinical, pathologic, and dosimetric parameters have been iden-
tified as predictors of PSA bounce, the authors found that only
younger age has consistently been associated with PSA bounce.
Our study suggests that this association can be extended to prostate
cancer patients undergoing SBRT.
Sheinbein and colleagues performed an analysis of clini-
cal, pathologic, and dosimetric parameters associated with PSA
bounce in 102 patients undergoing IMRT for localized prostate
cancer (13). They reported a PSA bounce rate of 32.4%. Only
age ≤70 was associated with PSA bounces; all other parameters
studied were not found to be correlated with PSA bounces.
The reasons why younger patients more frequently experience
PSA bounces are unknown. One common etiology suggested is
that younger men have increased androgen levels (9, 16). Another
frequently cited explanation is the increased sexual activity in
younger men (16, 17). Recent sexual activity could possibly lead
to spurious PSA elevations, and Das et al. reported that a common
cause of PSA bounces is recent ejaculation (15). However, Crook
et al. found that pre-treatment potency was a univariate predic-
tor of PSA bounce, but this association was lost on multivariate
analysis (18).
Table 3 | Review of previous prostate SBRT studies.
Study Number of
patients
PSA bounce definition PSA bounce
frequency (%)
Median bounce
size (ng/mL)
Median time to PSA
bounce (months)
King et al. (4) 41 Increase of ≥0.2 ng/mL followed by decline
to or below previous nadir
29 0.39 18
Lee et al. (14) 29 Increase of ≥0.2 ng/mL followed by decline
to or below previous nadir
28 0.69 9
McBride et al. (5) 45 Increase of ≥0.4 ng/mL followed by decline
to or below previous nadir
20 1.07 11.6
Chen et al. (2) 100 Increase of ≥0.2 ng/mL followed by decline
to or below previous nadir
31 0.5 15
Katz et al. (3) 304 Increase of >0.2 ng/mL from nadir 17 0.55 30
Present study 120 Increase of ≥0.2 ng/mL followed by decline
to or below previous nadir
28 0.5 9
SBRT, stereotactic body radiation therapy; PSA, prostate-specific antigen.
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Limitations of this study include its retrospective design, small
sample size, and relatively short follow-up period. It is possible
that some factors did not achieve statistical significance because
the study was underpowered and not enough patients were stud-
ied. Larger studies with longer follow-up are needed to determine
if any other factors can predict PSA bounce in prostate SBRT
patients.
CONCLUSION
We report the incidence of PSA bounce in our series of prostate
SBRT patients to be 28%, in-line with other institutions’ expe-
riences. As observed in studies that used brachytherapy or other
types of EBRT, we identified age as the only clinical factor that
predicts PSA bounce.
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